Drug General Information
Drug ID	D0B5HF
Former ID	DNCL002837
Drug Name	BI-135585
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 1	[523331]
Company	Boehringer Ingelheim Pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Corticosteroid 11-beta-dehydrogenase, isozyme 1	Target Info	Modulator	[551800]
KEGG Pathway	Steroid hormone biosynthesis
	Metabolism of xenobiotics by cytochrome P450
	Metabolic pathways
	Chemical carcinogenesis
NetPath Pathway	IL1 Signaling Pathway
	FSH Signaling Pathway
PathWhiz Pathway	Steroidogenesis
Reactome	Glucocorticoid biosynthesis
WikiPathways	Prostaglandin Synthesis and Regulation
	Metabolism of steroid hormones and vitamin D
	Glucocorticoid & Mineralcorticoid Metabolism
References
Ref 523331	ClinicalTrials.gov (NCT01282970) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
Ref 551800	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.